Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Floxuridine/Dexamethasone + Systemic Oxaliplatin/Capecitabine for Resected Colorectal Liver Metastases
NCT00026234Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2002
- Primary completion
- Jan 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine, oxaliplatin and capecitabine in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoints: Toxicity of oxaliplatin at 6 months and Survival rate at 2 years. Started Feb 2002; status: completed.
02
Drugs
floxuridineoxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00026234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026234.